Navigation Links
BUMC, BMC receives Clinical and Translational Science Award from NIH
Date:5/29/2008

Boston, MA--The National Institutes of Health (NIH) has awarded one of 14 Clinical and Translational Science Awards (CTSA) for 2008 to a team based at Boston University Medical (BUMC) and Charles River Campuses and Boston Medical Center (BMC). These awards, together with 12 CTSAs awarded in 2007, and 12 awarded in 2006, form the core of an NIH effort to build a national consortium of select centers that will transform how clinical and translational research is conducted, ultimately enabling researchers to provide new and better treatments more efficiently and quickly to patients.

The Boston University Clinical and Translational Science (BU-BRIDGE) Institute will integrate, connect and expand research and programs across traditional academic departments and schools. The institute will be a bridge between disciplines to facilitate interactions by incorporating multiple key programs that support the university-wide commitment to a home for translational research.

The BU-BRIDGE Institute will build on a strong foundation of relationships and trust that presently exists. Moreover, we expect the Institute and its community engagement function to have a transformative effect on clinical and translational research at BUMC by infusing community-based needs and perspectives throughout the Institutes work, said David Center, MD, principal investigator for this project and associate provost for Translational Research, the Gordon and Ruth Snider Professor of Pulmonary Medicine at BUSM and Chief, Pulmonary, Allergy and Critical Care Medicine at BMC.

Importantly, the Institute will provide the administrative structure and process, as well as financial resources, to significantly extend and enhance our successful partnering with our community, Center added.

The CTSA will allow the Institute to build on existing strengths to create an environment linking faculty, trainees and university programs to speed the translation of innovations in medical science to improve maintenance of health and diagnosis and treatment of diseases and share these innovations with other University based Clinical and Translational Science Institute's. The BU-BRIDGE environment will also support the bi-directional development and translation of ideas that begin in the clinic to the BU scientific community and back to identify new ways to improve health and delivery of health care services. Moreover, the Institute will significantly enhance existing partnerships with Boston's community health centers, transforming the conduct of clinical and translational research by infusing it with community based perspectives and needs.

Our program is a confirmation of the close collaboration among the three Boston University Medical Campus schools, Boston Medical Center, the Boston HealthNet Health Centers and Boston Universitys Charles River Campus, said Karen Antman, MD, dean of Boston University School of Medicine and provost of Boston University Medical Campus.

With more than half of NIHs funding allocated for basic research, the CTSA consortium is perfectly poised to help move discoveries in the laboratory to improved patient care. The consortium serves as the bridge in this process that allows researchers to perfect and refine existing treatments through interdisciplinary teams that extend to the clinic and community, said NIH Director Elias A. Zerhouni, MD. Through the consortium, we are better able to leverage expertise and resources across the CTSA institutions, and ultimately maximize NIHs investment in basic research, which should remain a top priority.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8491
Boston University
Source:Eurekalert

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... ... solutions for drugs, biologics and consumer health products, today announced that two of ... validation of bioassays at two upcoming conferences. , At the BEBPA 10th Annual ...
(Date:9/25/2017)... , ... September 25, 2017 , ... ... affiliated with NCPDP, announced today that it has awarded a $40,000 grant to ... NCPDP’s SCRIPT Standard for ePrescribing. CancelRx enables prescribers to electronically cancel a prescription ...
(Date:9/25/2017)... ... September 25, 2017 , ... Lean Management techniques ... principle of First-Defect-Stop for laboratory weighing is designed to help laboratory ... to have negative consequences on downstream processes. , If a problem is detected, ...
(Date:9/25/2017)... ... September 25, 2017 , ... Bioclinica®, ... today announces that 30 of its domain experts will present on a ... upcoming industry conferences and webinars. Drawing on broad and deep industry experience ...
(Date:9/25/2017)... , ... September 25, 2017 , ... ... retirement is not an option to senior, upper-level executives speaking at a business ... , "A senior, high-level executive is an asset to be fully realized and ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017  PMD ... OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... strategic hub service that expedites and streamlines patient and ... Spiro PD 2.0, and wellness management services.  ... medical device used to measure lung function for a ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
Breaking Medicine Technology: